Role of prostacyclin in pulmonary hypertension

Global Cardiology Science & Practice
Jane A MitchellNura Mohamed

Abstract

Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vessels. Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance in the balance of these factors leads to cardiovascular disease including pulmonary arterial hypertension. Since it's discovery in the 1970s concerted efforts have been made to make the best therapeutic utility of prostacyclin, particularly in the treatment of pulmonary arterial hypertension. This has centred on working out the detailed pharmacology of prostacyclin and then synthesising new molecules based on its structure that are more stable or more easily tolerated. In addition, newer molecules have been developed that are not analogues of prostacyclin but that target the receptors that prostacyclin activates. Prostacyclin and related drugs have without doubt revolutionised the treatment and management of pulmonary arterial hypertension but are seriously limited by side effects within the systemic circulation. With the dawn of nanomedicine and targeted drug or stem cell delivery systems it will, in the very near future, be possible to make new formulations of prostacyclin that can evade the systemic circulation allowing for safe delivery to t...Continue Reading

References

Dec 1, 1976·Prostaglandins·N WhittakerF F Sun
Jul 9, 1992·The New England Journal of Medicine·B W ChristmanJ E Loyd
Apr 15, 1989·The Biochemical Journal·W L Smith
Feb 1, 1996·The New England Journal of Medicine·R J BarstUNKNOWN Primary Pulmonary Hypertension Study Group
Jun 3, 1999·American Journal of Respiratory and Critical Care Medicine·R M TuderN F Voelkel
Jul 13, 2000·The Journal of Biological Chemistry·E M SmythG A FitzGerald
Sep 13, 2002·American Journal of Physiology. Lung Cellular and Molecular Physiology·D A BradburyA J Knox
Nov 22, 2002·American Journal of Respiratory Cell and Molecular Biology·Xudong YangNicholas W Morrell
Jul 30, 2003·Proceedings of the National Academy of Sciences of the United States of America·Timothy D Warner, Jane A Mitchell
Jun 15, 2004·European Journal of Pharmacology·Vincent GiguèreJean-Luc Parent
Jun 29, 2004·American Journal of Physiology. Lung Cellular and Molecular Physiology·Karen K K ShearesNicholas W Morrell
Oct 22, 2005·American Journal of Respiratory Cell and Molecular Biology·Ferhana Y AliJane A Mitchell
Dec 22, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Ferhana Y AliJane A Mitchell
Feb 18, 2006·Nature Reviews. Drug Discovery·Jane A Mitchell, Timothy D Warner
Apr 1, 2008·The Journal of Pharmacology and Experimental Therapeutics·Mary-Clare CathcartGraham P Pidgeon
Aug 26, 2009·British Journal of Pharmacology·Maria G Belvisi, Jane A Mitchell
Oct 20, 2009·Basic Research in Cardiology·Kiyoko TakemiyaTsutomu Imaizumi
Mar 2, 2010·Nature Reviews. Drug Discovery·UNKNOWN International Transporter ConsortiumLei Zhang
May 15, 2010·Science·Tatum S SimonsonRiLi Ge
Oct 26, 2010·Journal of Molecular and Cellular Cardiology·Richard C HewerMark Bond
Jun 15, 2011·The Journal of Clinical Investigation·Yannis HaraJean-Sébastien Hulot
Oct 25, 2011·American Journal of Respiratory Cell and Molecular Biology·Yingji LiAndrea Olschewski
Mar 1, 2012·The European Respiratory Journal·Gérald SimonneauIrene M Lang
Mar 28, 2012·Methods in Enzymology·W MosgoellerA Zimmer
Apr 10, 2012·Pharmacology & Therapeutics·Peter M GeorgeJane A Mitchell
Oct 10, 2012·Proceedings of the National Academy of Sciences of the United States of America·Nicholas S KirkbyJane A Mitchell
Jun 25, 2013·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Nicholas S KirkbyJane A Mitchell

❮ Previous
Next ❯

Citations

May 2, 2019·The Cochrane Database of Systematic Reviews·Hayley BarnesTrevor Williams
Jul 14, 2020·Current Opinion in Nephrology and Hypertension·Daniel L Edmonston, Matthew A Sparks
Oct 19, 2017·Drugs·A AtallahV Tsatsaris
Jan 9, 2019·Frontiers in Cardiovascular Medicine·Gayathri ViswanathanSudarshan Rajagopal
Aug 14, 2019·Heart Failure Reviews·Michail PapamichalisFilippos Triposkiadis
May 20, 2020·Current Pharmaceutical Design·Michele PauloLusiane M Bendhack
Oct 28, 2020·Journal of Clinical Medicine·Hien C NguyenKrishna K Singh
Jan 14, 2021·Biomedicines·Kondababu KurakulaMarie-José Goumans
Jul 9, 2020·Pharmacology & Therapeutics·Jane A MitchellTimothy D Warner
Sep 17, 2021·Molecular and Cellular Biochemistry·Rahul Mallick, Asim K Duttaroy
Sep 17, 2021·The Egyptian Heart Journal : (EHJ) : Official Bulletin of the Egyptian Society of Cardiology·Eka Prasetya Budi Mulia, Kevin Luke

❮ Previous
Next ❯

Software Mentioned

GRIPHON

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.